Therapy Type: Small Molecule (timeline)
Target Type: Unknown
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Inactive)
Sabeluzole has been reported to reduce glutatmate toxicity in part by reducing NMDA-induced inward current (Van der Valk et al., 1993). It also has been shown to affect cytoskeletal stability (Geerts et al., 1996) and tau expression (Uberti et al., 1997).
- Van der Valk JB, Vijverberg HP. Chronic sabeluzole treatment of cultured rat cerebellar granule cells reduces N-methyl-D-aspartate-induced inward current. Eur J Pharmacol. 1993 Feb 23;232(1):131-4. PubMed.
- Geerts H, Nuydens R, De Jong M, Cornelissen F, Nuyens R, Wouters L. Sabeluzole stabilizes the neuronal cytoskeleton. Neurobiol Aging. 1996 Jul-Aug;17(4):573-81. PubMed.
- Uberti D, Rizzini C, Galli P, Pizzi M, Grilli M, Lesage A, Spano P, Memo M. Priming of cultured neurons with sabeluzole results in long-lasting inhibition of neurotoxin-induced tau expression and cell death. Synapse. 1997 Jun;26(2):95-103. PubMed.
No Available Further Reading